Franciskos Arsenyadis

Mr. Franciskos Arsenyadis

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
TYThomas Yates
Thomas Yates
GBGregory Biddle
Gregory Biddle
JHJ. Henson
J. Henson
CEC. L. Edwardson
C. L. Edwardson
FAFranciskos Arsenyadis
Franciskos Arsenyadis
MDMelanie J Davies
Melanie J Davies
Aim: In a primary care population at high risk of type 2 diabetes, 24‐month weight change trajectories were used to investigate the impact of weight cycling on fat mass (FM) and fat‐free mass (FFM). Materials and Methods: Cohort data from the Walking Away from Type 2 Diabetes trial was used, which recruited adults at‐risk of type 2 diabetes from primary care in 2009/10. Annual weight change trajectories based on weight loss/gain of ≥5% were assessed over two 24‐month periods. Body composition was measured by bioelectrical impedance analysis. Repeated measures were analysed using generalized estimating equations with participants contributing up to two 24‐month observation periods. Results: In total, 622 participants were included (average age = 63.6 years, body mass index = 32.0 kg/m 2 , 35.4% women), contributing 1163 observations. Most observations (69.2%) were from those that maintained their body weight, with no change to FM or FFM. A minority (4.6% of observations) lost over 5% of body weight between baseline and 12 months, which was then regained between 12 and 24 months. These individuals regained FM to baseline levels, but lost 1.50 (0.66, 2.35) kg FFM, adjusted for confounders. In contrast, those that gained weight between baseline and 12 months but lost weight between 12 and 24 months (5.5% of observations) had a net gain in FM of 1.70 (0.27, 3.12) kg with no change to FFM. Conclusion: Weight cycling may be associated with a progressive loss in FFM and/or gain in FM in those with overweight and obesity at‐risk of type 2 diabetes.

30 July 2025 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
James KingJames King
James King
ATAlice Thackray
Alice Thackray
CGCatherine Gibbons
Catherine Gibbons
CMCatia Martins
Catia Martins
DBDavid Broom
David Broom
DTDavid Thivel
David Thivel
Appetite control is a topic which attracts widespread interest given its importance to energy balance and obesity. In this research area, the mixed-meal tolerance test (MM-TT) has emerged as an ‘ appetite regulation assay’ , facilitating the dynamic assessment of appetite parameters (e.g. subjective appetite perceptions, appetite-related hormones, food reward) in response to an individual meal. The MM-TT is commonly employed in observational and experimental studies to examine population differences and intervention effects. Problematically, no practice standard exists for the MM-TT and protocols vary widely. This presents a challenge for researchers designing new MM-TTs and hampers the comparability of findings. Therefore, within this narrative review we sought to identify and discuss key methodological considerations inherent within a MM-TT. The scope of our review extends to evaluating participant familiarisation and methodological standardisation practices, test meal characteristics, appetite perception assessment, blood sampling techniques, measurement of appetite-related hormones and data handling/analysis. A checklist has been devised to summarise relevant methodological issues identified within this review. This checklist can be used as a tool by researchers to facilitate MM-TT design and promote greater standardisation/comparability between studies. This review highlights the need for broader standardisation of MM-TT procedures to support consistency across future research. Additional research is needed to strengthen the evidence base on which various recommendations are made, particularly relating to participant familiarisation and methodological standardisation practices. Additional scrutiny of less common outcomes employed in MM-TTs (not addressed here), such as diet-induced thermogenesis, gastric emptying and ad libitum energy intake, is also needed.

27 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
FAFranciskos Arsenyadis
Franciskos Arsenyadis
EAEhtasham Ahmad
Ehtasham Ahmad
EREmma Redman
Emma Redman
TYThomas Yates
Thomas Yates
MDMelanie J Davies
Melanie J Davies
KKKamlesh Khunti
Kamlesh Khunti
Background: Omega-3 polyunsaturated fatty acids′ concurrent benefits for cardiometabolic and mental health are equivocal. Despite lack of evidence, up to a third of adults consume Omega-3 supplements. No review has yet been published to report effect on depression in this cardiometabolic population. Methods: We conducted a systematic review of double-blinded, controlled randomised trials to investigate the safety and effect of Omega-3 supplementation on depression scores in people with cardiometabolic diseases. Primary outcome was change in depression scores versus placebo. Secondary outcomes were side-effects, concurrent medication and adherence. Results: Seven trials reporting on 2575 (672 female) adults aged 39–73 were included. Omega-3 dosages ranged from 1–3 g with an intervention duration of 10–48 weeks. Six out of seven trials found no statistically or clinically significant change to depression scores compared to placebo. One trial favoured intervention (Relative Risk Reduction: 47.93%, 95% CI: 24.89–63.98%, p < 0.001). Sub-analyses showed clinically meaningful reductions in depression scores for those on antidepressants (Intervention: 20.9 (SD: 7.1), Placebo: 24.9 (SD: 8.5) p < 0.05) or with severe depression (−1.74; 95% CI −3.04 to −0.05, p < 0.05) in two separate trials. Side effects were comparable between treatment arms. Conclusions: Omega-3 supplementation is safe to use but not superior to placebo for depression in adults with concurrent cardiometabolic disease.

5 September 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
SKStanislava Katsarova
Stanislava Katsarova
EREmma Redman
Emma Redman
FAFranciskos Arsenyadis
Franciskos Arsenyadis
EBEmer Brady
Emer Brady
ARAlex Rowlands
Alex Rowlands
JHJoseph Henson
Joseph Henson
Chronotype studies investigating dietary intake, eating occasions (EO) and eating windows (EW) are sparse in people with type 2 Diabetes mellitus (T2DM). This analysis reports data from the CODEC study. The Morningness-Eveningness questionnaire (MEQ) assessed chronotype preference. Diet diaries assessed dietary intake and temporal distribution. Regression analysis assessed whether dietary intake, EW, or EO differed by chronotype. 411 participants were included in this analysis. There were no differences in energy, macronutrient intake or EW between chronotypes. Compared to evening chronotypes, morning and intermediate chronotypes consumed 36.8 (95% CI: 11.1, 62.5) and 20.9 (95% CI: −2.1, 44.1) fewer milligrams of caffeine per day, respectively. Evening chronotypes woke up over an hour and a half later than morning (01:36 95% CI: 01:09, 02:03) and over half an hour later than intermediate chronotypes (00:45 95% CI: 00:21; 01:09. Evening chronotypes went to sleep over an hour and a half later than morning (01:48 95% CI: 01:23; 02:13) and an hour later than intermediate chronotypes (01:07 95% CI: 00:45; 01:30). Evening chronotypes’ EOs and last caffeine intake occurred later but relative to their sleep timings. Future research should investigate the impact of chronotype and dietary temporal distribution on glucose control to optimise T2DM interventions.

17 November 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
FAFranciskos Arsenyadis
Franciskos Arsenyadis
EREmma Redman
Emma Redman
JHJoseph Henson
Joseph Henson
EBEmer M. Brady
Emer M. Brady
NCNicole A. Coull
Nicole A. Coull
MDMelanie J Davies
Melanie J Davies
Click on the article title to read more.

23 March 2026 in BMJ Open
Verified
Journal Article
Open access
FAFranciskos Arsenyadis
Franciskos Arsenyadis
JHJoseph Henson
Joseph Henson
MMMatthew McCarthy
Matthew McCarthy
DPDimitris Papamargaritis
Dimitris Papamargaritis
JKJames A King
James A King
TYThomas Yates
Thomas Yates
Introduction: The global prevalence of type 2 diabetes (T2D) is rising and disproportionately affects South Asian adults, including those in the United Kingdom. South Asians develop T2D at a higher rate and at a younger age than their white British counterparts, at a lower body mass index. Active efforts to reduce adiposity can improve glycaemic control and in some cases achieve T2D remission. However, a substantial proportion of lean mass is lost while achieving weight loss, which may have physiological and metabolic consequences, affecting long-term health outcomes and quality of life for people living with T2D and obesity. We are examining the impact of a combined low energy diet and supervised exercise intervention versus a low energy diet alone for the preservation of lean mass in an understudied South Asian population living with T2D and excess adiposity. Methods and analysis: This prospective, randomised, two-arm parallel-group, open-label, blinded-endpoint trial is being conducted in Leicester, UK. 36 South Asian adults aged 40–65 years within 10 years of T2D diagnosis and not on insulin therapy will be enrolled. Both intervention arms will receive an 800–900 kcal/day low energy diet for 12 weeks. Those randomised to the exercise group will additionally receive a mixture of supervised and home-based resistance and aerobic exercise training three times per week. The primary outcome is the difference in the change of lean mass between groups measured using dual-energy X-ray absorptiometry at baseline and 12 weeks and will be analysed using linear regression modelling. Ethics and dissemination: The trial was approved by the NHS research ethics service (23/WM/0201). All participants will provide informed consent prior to enrolment, and the study will be conducted in accordance with the Declaration of Helsinki. Findings will be shared widely (publications, presentations, press releases, social media platforms) and will inform an effectiveness trial. Trial registration number: ISRCTN11175684 .